Clinical practice guideline advises against erythropoiesis-stimulating agents for mild-to-moderate anemia in heart disease, indicating unfavorable risk-benefit profiles.
ACP recommends against the use of erythropoiesis-stimulating agents in patients with mild to moderate anemia and congestive heart failure or coronary heart disease. (Grade: strong recommendation; moderate-quality evidence).
No takes yet. Share an insight, caveat, or question.
Qaseem et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: